ANTONIO ESTEVES FILHO

Índice h a partir de 2011
5
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Indexador: PubMed ×

Resultados de Busca

Agora exibindo 1 - 2 de 2
  • article
    Type 4 Dual Left Anterior Descending Artery: A Very Rare Coronary Anomaly Circulation
    (2015) OLIVEIRA, Marcos Danillo Peixoto; MELO, Pedro H. M. Craveiro de; ESTEVES FILHO, Antonio; KAJITA, Luiz J.; RIBEIRO, Expedito E.; LEMOS, Pedro Alves
    Coronary artery anomalies are congenital changes in their origin, course, and/or structure. They are the second most frequent cause of sudden death in young athletes. Dual LAD artery is a rare coronary anomaly. We present the case of a 44-year-old man with recent onset exertional angina and documented ischemia whose coronary angiogramand computed tomography (CT) showed type 4 dual LAD artery, the rarest and most interesting variant.
  • article
    Clinical performance of a novel ultrathin strut, low-dose, sirolimus-eluting stent with abluminal-only biodegradable polymeric coating for patients undergoing percutaneous coronary intervention in the daily practice
    (2015) PRADO JR., Guy F. A.; RIBEIRO, Expedito E.; MELO, Pedro H. M. C.; PINTON, Fabio A.; ESTEVES-FILHO, Antonio; TAKIMURA, Celso K.; MARIANI JR., Jose; KAJITA, Luiz J.; MARCHIORI, Gilberto; FALCAO, Breno de Alencar Araripe; GALON, Micheli Z.; SOARES, Paulo R.; ZALC, Silvio; LEMOS, Pedro A.
    Background: The present study aimed to evaluate the clinical performance, in the daily practice of a busy catheterization laboratory, of a novel drug-eluting stent (DES) built with an ultra-thin-strut metallic platform, eluting sirolimus at low doses, abluminal coated with biodegradable polymers, and mounted in a low-compliant delivery system. Methods: Prospective, single-arm study, comprising all consecutive patients undergoing percutaneous coronary intervention (PCI) with the Inspiron (TM) sirolimus-eluting stent (SES) (Scitech, Aparecida de Goiania, Brazil). The primary endpoint was the occurrence of major adverse cardiac events (MACE) [cardiac death, non-PCI related myocardial infarction (MI), or target vessel revascularization (TVR)]. Results: A total of 470 patients were included, from which 51.3% were diabetics, 33.8% had triple-vessel disease, 15.3% had heart failure, 38.9% had at least one bifurcation treated, 19.8% were treated for a bare metal stent restenosis, and 61.9% had at least one type C lesion; one or more of these features were found in 96.0%. At 300 days, the rate target lesion revascularization was 5.4% and the rate of MACE was 8.1%. The incidence of definite or probable stent thrombosis was 0.4%, with no cases between 30 and 300 days. Conclusions: The novel stent is associated with excellent short and mid-term clinical outcomes in patients treated with PCI in the daily practice.